Pfizer Omicron vaccine receives FDA authorization for children

Pfizer's Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine received FDA emergency use authorization for use for children six months through four years of age as a third dose.

“This authorization offers an opportunity for parents to help better protect their young children against COVID-19, including disease caused by Omicron sublineages,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Nearly 40 million Americans have received a booster dose of an updated vaccine. It is critical that we all continue to do our part to help protect ourselves by staying up to date with COVID-19 vaccinations, as recommended by public health authorities, especially now as we plan to gather for the holidays and head into the winter season.”

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy